Fig. 2.

(A) Prostate cancer–specific survival and (B) overall survival according to primary treatment groups among ProtecT cases. Death from prostate cancer occurred in two (4%) of the RP and 12 (5%) of the RT group (HR 0.95, CI 95% 0.22–4.12; p = 0.94). Death from all causes occurred in four (7%) of the RP and 37 (15%) of the RT group (HR 0.69, 95% CI 0.29–1.67; p = 0.41). A significantly greater proportion of the ADT group died from prostate cancer (n = 27, 22%) and all causes (n = 49, 40%) compared to men treated with radical therapy (p < 0.0001). RP = radical prostatectomy; RT = radical radiotherapy; ADT = androgen deprivation therapy; HR = hazard ratio; CI = confidence interval.